-- 加拿大帝国商业银行（CIBC）表示，新冠疫情或许已成过往，但加拿大医疗保健成本持续对各省财政造成巨大影响。 该银行在一份致客户的报告中指出，医疗保健支出占总支出的40%以上，一直是最大的单项支出。然而，近期医疗保健支出的影响更为显著，过去五年中，医疗保健支出增长的一半以上都来自医疗保健支出。 此外，这些成本增长并非总是易于预测，医疗保健支出也占近期预算超支的50%以上。 医疗支出需求的增长通常被归咎于通货膨胀，包括医务人员工资上涨和人口增长。尽管中东冲突再次引发了人们对通胀压力的担忧，但人口增长的急剧放缓理论上应该会缓解医疗保健成本的压力。 然而，不幸的是，还有另一个可能更大的因素在推高成本，而且这种情况在好转之前还会恶化。加拿大帝国商业银行（CIBC）指出，人口老龄化导致医疗保健成本上升，因为65岁以上人群的人均医疗支出呈指数级增长。 CIBC表示，如果人口老龄化继续按预期发展，那么医疗保健成本的总体增长幅度可能会超过各省目前的预测。
Related Articles
Australia
Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
$APTV$F
Research
Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
$CRTO
Australia
Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%
$OCUL